tovetumab tovetumab tovetumab is an anti-pdgfra monoclonal antibody designed for the treatment of cancer. it was developed by medimmune, and trialed for use in glioblastoma and non-small cell lung cancer. development was discontinued in 2013. tovetumabmonoclonal antibodytype?sourcehumantargetpdgfraclinical dataatc codenoneidentifierscas number1243266-04-7chemspidernoneunii2xy62k75uvkeggd10411chemical and physical dataformulac6400h9906n1726o2002s54molar mass144792.97 g·mol−1 this drug was developed by medimmune, llc.